| Leistung |
Fallzahl |
OPS-Schlüssel |
Info |
|
122
|
9-696.30 |
|
|
88
|
9-696.20 |
|
|
67
|
9-696.40 |
|
|
56
|
9-696.52 |
|
|
49
|
9-696.11 |
|
| Regelbehandlung bei psychischen und psychosomatischen Störungen und Verhaltensstörungen bei Kindern und Jugendlichen |
42
|
9-656 |
|
|
42
|
9-696.31 |
|
|
28
|
9-696.51 |
|
|
27
|
9-693.10 |
|
|
27
|
9-696.53 |
|
|
24
|
9-696.32 |
|
|
22
|
9-696.10 |
|
|
21
|
9-696.33 |
|
|
21
|
9-696.34 |
|
|
18
|
9-696.13 |
|
|
17
|
9-696.55 |
|
|
15
|
9-696.54 |
|
|
14
|
9-696.12 |
|
|
14
|
9-696.35 |
|
|
14
|
9-696.36 |
|
|
11
|
9-696.50 |
|
|
10
|
9-693.11 |
|
|
10
|
9-696.14 |
|
|
10
|
9-696.37 |
|
|
10
|
9-696.56 |
|
|
9
|
9-696.15 |
|
|
9
|
9-696.16 |
|
|
8
|
9-696.21 |
|
|
8
|
9-696.57 |
|
|
8
|
9-696.58 |
|
| Psychiatrisch-psychosomatische Intensivbehandlung bei psychischen und psychosomatischen Störungen und Verhaltensstörungen bei Kindern und Jugendlichen |
7
|
9-672 |
|
|
5
|
9-696.38 |
|
|
5
|
9-696.59 |
|
|
5
|
9-696.5c |
|
|
4
|
9-696.17 |
|
|
4
|
9-696.18 |
|
|
4
|
9-696.19 |
|
|
4
|
9-696.5a |
|
| Applikation von Medikamenten, Liste 5: Tocilizumab, subkutan: 1.296 mg bis unter 1.458 mg 1.296 mg bis unter 1.458 mg |
k.A.
|
6-005.n7 |
|
|
k.A.
|
9-696.1a |
|
|
k.A.
|
9-696.1b |
|
|
k.A.
|
9-696.1c |
|
|
k.A.
|
9-696.39 |
|
|
k.A.
|
9-696.3a |
|
|
k.A.
|
9-696.3b |
|
|
k.A.
|
9-696.3c |
|
|
k.A.
|
9-696.3d |
|
|
k.A.
|
9-696.3e |
|
|
k.A.
|
9-696.3g |
|
|
k.A.
|
9-696.41 |
|
|
k.A.
|
9-696.5b |
|
|
k.A.
|
9-696.5d |
|
|
k.A.
|
9-696.5e |
|
|
k.A.
|
9-696.5f |
|
|
k.A.
|
9-696.5g |
|
|
k.A.
|
9-696.5m |
|
|
k.A.
|
9-984.8 |
|
